Leflunomide in treatment of RA patents preliminary estimation of therapeutical efficiency and side effects
Journal Title: Reumatologia - Year 2006, Vol 44, Issue 1
Abstract
In the preliminary estimation there were studied efficiency and safety of therapy leflunomid in patients with RA. The drug was given p. o. to a group of 158 patients (150 females and 8 males) for 3 days 100 mg/24 h, and then again 20 mg/24 h. The age of patients varied between 19-78 (average age was 55 years), with average duration time of the disease 10 years and 2 months. All of the patients were previously unsuccessfully treated with other DMARDS. All of the patients had high activity of disease estimated by DAS 28 ≥5.1 61.4% of patients were treated with long-term glicocorticosteroids. Time of trial was scheduled for 6 months. The therapeutical effect was initially estimated on the basis of a group of 43 patients who took the medicine for 91-120 days. Good and average therapeutical efficiency of treatment was observed in 76.73% of patients. Efficiency was expressed by lowering DAS 28 by 0.6-1.2 in a group of 11.62% of patients and 1.2 in a group of 65.11% of patients. In a group of 3.79% of patients the treatment was stopped because of complete lack of therapeutical effect. Frequency of side effects was initially estimated in a group of 158 patients. Treatment was interrupted in the group of 8.86% of patients because of such side effects as: diarrheas, elevation of transaminazes, leukopenia and trombocytopenia, skin changes and dizziness. Observations are continued. Preliminary results of observations allow for positive evaluation of treatment with leflunomid in RA patients.
Authors and Affiliations
Maria Rell-Bakalarska, Janusz Jaworski, Lidia Rutkowska-Sak, Małgorzata Wieczorek, Ewa Klimczak, Bożena Kowalczuk, Krzysztof Wojciech Rell
Keywords
Related Articles
- EP ID EP144333
- DOI -
- Views 45
- Downloads 0
Ocena jakości życia pacjentów z reumatoidalnym zapaleniem stawów
Reumatoidalne zapalenie stawów (RZS) jest przewlekłą, zapalną, układową chorobą tkanki łącznej, prowadzącą do niepełnosprawności, inwalidztwa i przedwczesnej śmierci. Przewlekły i okaleczający charakter RZS oraz ogranicz...
Przeciwciała przeciwjądrowe w zespole suchości – charakterystyka antygenowa i znaczenie kliniczne
W pracy przedstawiono charakterystykę antygenową i znaczenie kliniczne przeciwciał przeciwjądrowych w rozpoznaniu zespołu suchości. Omówiono równie¿ metody ich wykrywania oraz związek przeciwciał z objawami klinicznymi...
Evaluation of 12-lead resting ECG with QTc analysis in children with systemic and localized scleroderma
Scleroderma is chronic inflammatory disease of connective tissue of unknown etiology. Classification into two forms: systemic and localized scleroderma depends on type of skin symptoms, kind of immunological disturbances...
Dna moczanowa – aktualne spojrzenie na diagnostykę i leczenie
Wpracy przedstawiono najnowsze doniesienia na temat współistnienia dny moczanowej oraz bezobjawowej hiperurykemii z zespołem metabolicznym. Biorąc pod uwagę wyniki naj now - szych badań, celowe wydaje się wczesne lecz...
Purpose of assessment of serum autoantibodies not included in CTD diagnostic criteria
In the paper the author discusses the importance of the so-called “auxiliary” autoantibodies – not included in the diagnostic criteria, but with a relatively high “specificity” (but not necessarily high sensitivity) for...